Comparison Between Cycles of the Same Patients when Using Recombinant Luteinizing Hormone + Recombinant Follicle Stimulating Hormone (rFSH), Human Menopausal Gonadotropin + RFSH and RFSH Only

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2019 May 22

PMID 31110533

Citations 6

Authors

Ahter Tanay Tayyar

Semra Kahraman

Affiliations

Soon will be listed here.

Abstract

Introduction: Recombinant follicle stimulating hormone (rFSH), recombinant luteinizing hormone (rLH), and urinary human menopausal gonadotropin (uHMG) are widely used for controlled ovarian stimulation (COS). This study compares the effects of rFSH only, rLH + rFSH, and HMG + rFSH administration on fertilization (IVF) outcomes for patients in three different yearly follow-up cycles.

Material And Methods: This retrospective, single-center cohort study was conducted from January 2001 to June 2016 at Istanbul Memorial Hospital, Artificial Reproductive Technology Center. From a total of 27,024 IVF cycles in women aged 18 to 45 years (17,536 rFSH only; 2147 rLH + rFSH; 7341 HMG + rFSH), the results of 2,147 cycles receiving a treatment of rLH + rFSH over the 3-year evaluation and 2,081 total cycles in which rLH + rFSH was used at least once were evaluated, and different gonadotropin combinations were compared.

Results: The age and body mass index of the patients in the uHMG + rFSH group were found to be significantly higher than those of the patients in the rLH + rFSH and rFSH only groups ( < 0.001). The total gonadotropin (GND) dosage of the patients in the rLH + rFSH group was found to be significantly lower than that of the HMG + rFSH group ( = 0.001). No statistically significant differences were found between the clinical and ongoing pregnancy rates, while the highest clinical and ongoing pregnancy rate was observed in the rLH + rFSH group at age 35-39 years.

Conclusions: Recombinant luteinizing hormone administration may increase the number of clinical pregnancies for patients aged 35-39 years.

Citing Articles

Assisted Reproductive Technology Outcomes in Women with Normal Ovarian Response Receiving Recombinant Luteinizing Hormone/Human Menopausal Gonadotropin: An Observational Study.

Liang Y, Hou X, Chen H, Yang R, Wang R, Mao R Int J Womens Health. 2024; 16:1103-1111.

PMID: 38895039 PMC: 11185249. DOI: 10.2147/IJWH.S454410.

A novel role of follicle-stimulating hormone (FSH) in various regeneration-related functions of endometrial stem cells.

Park S, Kim S, Kim S, Park J, Hong I Exp Mol Med. 2022; 54(9):1524-1535.

PMID: 36117220 PMC: 9534881. DOI: 10.1038/s12276-022-00858-1.

Novel roles of luteinizing hormone (LH) in tissue regeneration-associated functions in endometrial stem cells.

Park S, Kim S, Kim S, Park J, Lim S, Hong I Cell Death Dis. 2022; 13(7):605.

PMID: 35831270 PMC: 9279474. DOI: 10.1038/s41419-022-05054-7.

Follicular and serum levels of vitamin D in women with unexplained infertility and their relationship with fertilization outcome: an observational pilot study.

Jeremic A, Mikovic Z, Soldatovic I, Sudar-Milovanovic E, Isenovic E, Perovic M Arch Med Sci. 2021; 17(5):1418-1422.

PMID: 34522272 PMC: 8425239. DOI: 10.5114/aoms/141185.

Interplay Between mTOR and Hippo Signaling in the Ovary: Clinical Choice Guidance Between Different Gonadotropin Preparations for Better IVF.

Papageorgiou K, Mastora E, Zikopoulos A, Grigoriou M, Georgiou I, Michaelidis T Front Endocrinol (Lausanne). 2021; 12:702446.

PMID: 34367070 PMC: 8334720. DOI: 10.3389/fendo.2021.702446.

References

Lindheim S, Morales A . GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod. 2003; 18(10):2048-51. DOI: 10.1093/humrep/deg407. View

Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E . Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online. 2004; 8(2):175-82. DOI: 10.1016/s1472-6483(10)60513-5. View

Humaidan P, Bungum M, Bungum L, Andersen C . Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online. 2004; 8(6):635-43. DOI: 10.1016/s1472-6483(10)61643-4. View

Wolfenson C, Groisman J, Couto A, Hedenfalk M, Cortvrindt R, Smitz J . Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online. 2005; 10(4):442-54. DOI: 10.1016/s1472-6483(10)60819-x. View

Filicori M, Cognigni G, Gamberini E, Parmegiani L, Troilo E, Roset B . Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005; 84(2):394-401. DOI: 10.1016/j.fertnstert.2005.02.036. View

Tarlatzis B, Tavmergen E, Szamatowicz M, Barash A, Amit A, Levitas E . The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod. 2005; 21(1):90-4. DOI: 10.1093/humrep/dei293. View

Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri M . Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril. 2006; 87(3):542-6. DOI: 10.1016/j.fertnstert.2006.06.059. View

Mochtar M, Van der Veen , Ziech M, van Wely M . Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2007; (2):CD005070. DOI: 10.1002/14651858.CD005070.pub2. View

ODea L, OBrien F, Currie K, Hemsey G . Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 2008; 24(10):2785-93. DOI: 10.1185/03007990802374815. View

10.

Trew G, Brown A, Gillard S, Blackmore S, Clewlow C, ODonohoe P . In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review. Reprod Biol Endocrinol. 2010; 8:137. PMC: 2993713. DOI: 10.1186/1477-7827-8-137. View

11.

Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A . Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2010; 95(3):1031-6. DOI: 10.1016/j.fertnstert.2010.10.021. View

12.

Wong P, Qiao J, Ho C, Ramaraju G, Wiweko B, Takehara Y . Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online. 2011; 23(1):81-90. DOI: 10.1016/j.rbmo.2011.03.023. View

13.

Buhler K, Fischer R . Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study. Gynecol Endocrinol. 2011; 28(5):345-50. DOI: 10.3109/09513590.2011.633128. View

14.

Cavagna M, Braga D, Biaggioni Lopes F, Figueira R, Iaconelli Jr A, Borges Jr E . The effect of GnRH analogues for pituitary suppression on ovarian response in repeated ovarian stimulation cycles. Arch Med Sci. 2012; 7(3):470-5. PMC: 3258761. DOI: 10.5114/aoms.2011.23414. View

15.

van Wely M, Kwan I, Burt A, Thomas J, Vail A, van der Veen F . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. Hum Reprod Update. 2012; 18(2):111. DOI: 10.1093/humupd/dmr048. View

16.

Hill M, Levens E, Levy G, Ryan M, Csokmay J, DeCherney A . The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril. 2012; 97(5):1108-14.e1. DOI: 10.1016/j.fertnstert.2012.01.130. View

17.

Dahan M, Agdi M, Shehata F, Son W, Tan S . A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or.... Eur J Obstet Gynecol Reprod Biol. 2013; 172:70-3. DOI: 10.1016/j.ejogrb.2013.10.027. View

18.

Konig T, van der Houwen L, Lambalk C . Reply: Comment on 'Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study'. Hum Reprod. 2014; 29(3):637-8. DOI: 10.1093/humrep/det432. View

19.

Lehert P, Kolibianakis E, Venetis C, Schertz J, Saunders H, Arriagada P . Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol. 2014; 12:17. PMC: 4015269. DOI: 10.1186/1477-7827-12-17. View

20.

Levi Setti P, Alviggi C, Colombo G, Pisanelli C, Ripellino C, Longobardi S . Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation. J Endocrinol Invest. 2014; 38(5):497-503. PMC: 4555088. DOI: 10.1007/s40618-014-0204-4. View